Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Regeneron Pharmaceuticals is conducting a Phase 3 clinical trial titled ‘An Open-label, Randomized, Phase 3 Study of Linvoseltamab (REGN5458; Anti- BCMA x Anti-CD3 Bispecific Antibody) Versus the Combination of Elotuzumab, Pomalidomide, and Dexamethasone (EPd), in Patients With Relapsed/Refractory Multiple Myeloma (LINKER-MM3)’. The study aims to evaluate the safety and effectiveness of linvoseltamab compared to a combination of three cancer drugs in patients with relapsed or refractory multiple myeloma.
The intervention being tested is linvoseltamab, an experimental bispecific antibody targeting BCMA and CD3, administered via intravenous infusion. It is compared against a combination of elotuzumab, pomalidomide, and dexamethasone, which are standard cancer treatments.
This interventional study is designed as a randomized, parallel assignment with no masking, focusing on treatment as the primary purpose. Participants are randomly assigned to receive either linvoseltamab or the EPd combination.
The study began on September 18, 2023, and is currently recruiting participants. The last update was submitted on June 23, 2025. These dates are crucial for tracking the study’s progress and potential market entry.
The outcome of this study could significantly influence Regeneron’s stock performance, as positive results might boost investor confidence and position the company favorably against competitors in the oncology market.
The study is ongoing, with further details available on the ClinicalTrials portal.